Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | |
---|---|---|---|
2020 | |||
Cost-effectiveness analysis of pembrolizumab compared to standard of care as first line treatment for patients with advanced melanoma in Hong Kong Journal:Cost Effectiveness and Resource Allocation | 2020 |